Navigation Links
Biotech Drops Amid Tough Markets in February
Date:3/3/2008

SAN FRANCISCO, March 3 /PRNewswire/ -- For the second month in a row the capital markets succumbed to fears of inflation and a weakening economy. On the last day of the month the Dow dropped over 300 points after oil prices pushed past $103 per barrel for the first time. Amid these fears, biotech was dragged down with the Burrill Biotech Select Index dropping 4% along with the NASDAQ, down 5% and the Dow, which closed down 3%.

"The biotech sector started 2008 on a positive note, outperforming the major indices in January," said G. Steven Burrill, CEO of Burrill & Company, a San Francisco based global leader in life sciences whose principal activities are in Private Equity, Venture Capital, Merchant Banking and Media. "However, in the wake of negative news from biotech's top performer Onyx Pharmaceuticals, the industry took a hit."

Onyx was the best-performing biotech stock of 2007, notching a one-year return of 440% ... but the company dropped 42.5% in February after reporting its cancer drug Nexavar failed a Phase III study in lung cancer patients. The study was testing the combination of Nexavar and the chemotherapy drugs carboplatin and paclitaxel in patients with non-small-cell lung cancer.

One of the few companies in the Index group to post a gain in February was Genentech (up 8%) on the strength that Avado, a Phase III study evaluating its cancer drug Avastin in combination with docetaxel chemotherapy, met its primary endpoint of prolonging progression-free survival in patients with advanced breast cancer. The Roche-sponsored Avado study investigated the addition of Avastin administered in two different dosages in combination with chemotherapy. Both doses of Avastin in combination with chemotherapy showed "statistically significant improvement" in the time patients lived without their disease advancing compared with chemotherapy and placebo.

The other was Illumina (up 13%). Its fourth-quarter revenue was up an impressive 86%. On the other side of the coin, shares of Vertex Pharmaceuticals were down 14% after reporting that a wider fourth-quarter loss will retard its 2008 outlook, which was below Wall Street expectations.

The Burrill Biotech Mid-Cap Index dropped 9% as investors migrated away from these companies. "Even though the pharmaceutical and biotech sectors are among the best for investors to be in during a recession, it is the blue-chip companies that they seek out. In difficult market conditions emerging biotech companies are viewed as more risky investments which is why most companies in the group lost value," noted Burrill.

Biotech IPOs remain on hold

The prevailing tough economic environment took its toll on biotech IPO "hopefuls" with Biolex, Light Sciences Oncology and Archemix cancelling their planned offerings because of the market conditions. Only one company braved the market -- Bioheart, a biotechnology company focused on using cells derived from a patient's body for treatment of heart damage. It priced its 1.1 million shares offering at $5.25 the midpoint of a revised range. The company had originally filed for an offering of 3.6 million shares at a range of $14-$16.

Market cap

The industry's market cap closed at $440 billion, unchanged for February. Genentech's market cap closed the month at $79B and second placed Amgen slipped 2% to $49B. Close on Amgen's heels is Gilead Sciences, which closed February at $44B.

Biotech Indices

Index 12/29/06 12/31/07 1/31/08 2/29/08 % %

change change

Month Year

Burrill Biotech

Select 303.96 331.52 331.31 318.05 -4.00% -4.06%

Burrill Large

Cap Biotech 424.56 437.71 438.87 434.25 -1.05% -0.79%

Burrill Mid-Cap

Biotech 171.55 201.89 179.33 161.7 -9.83% -19.91%

Burrill Small

Cap Biotech 143.6 137.6 148.3 150.15 1.25% 9.12%

Burrill Genomics 101.69 104.29 93.64 86.83 -7.27% -16.74%

Burrill AgBio 124.52 198.83 193.82 197.08 1.68% -0.88%

Burrill

Industrial 150.85 158.66 146.41 160.09 9.34% 0.90%

Burrill

Diagnostic 122.79 159.43 151.53 152.72 0.79% -4.21%

Burrill

Nutraceutical 629.56 593.04 556.24 546.94 -1.67% -7.77%

NASDAQ 2415.29 2652.28 2389.86 2271.48 -4.95% -14.36%

DJIA 12463.15 13264.82 12650.36 12266.39 -3.04% -7.53%

Russell 2000 787.66 766.03 713.3 686.18 -3.80% -10.42%

Amex Biotech 754.25 786.5 749.38 721.95 -3.66% -8.21%

Amex Pharma 345.06 338.52 316.45 305.15 -3.57% -9.86%


'/>"/>
SOURCE Burrill & Company
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Genetic Engineering & Biotechnology News reports on advances in miRNA
2. Microchip Biotechnologies, Inc. Collaborating With Stanford University on Developing a Front End Microfluidic-Based Sample Preparation System for Pyrosequencing Platforms
3. Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents
4. Sigma-Aldrich Names Helge Bastian New VP of Global Marketing for Research Biotech
5. Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
6. Biotech Pioneer William J. Rutter to Deliver Keynote at 2008 RAPS Horizons Conference
7. ZyGEM Appoints Leading Biotechnology Expert to Head Clinical Advisory Board
8. Marketing and Meeting Details (M2D) Offers Customized Convention Registration and Management Tool to Clients Inside and Outside of Pharma/Biotech
9. Biotech Crops Experience Remarkable Dozen Years of Double-Digit Growth
10. Raven biotechnologies to Provide Updates on Oncology Pipeline With Four AACR Presentations
11. Cord Blood America CEO Matthew Schissler Interviewed by BIONOVA, Greeces Leading Biotech Magazine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016 Houston Methodist Willowbrook Hospital ... Sports Association to serve as their official health ... Methodist Willowbrook will provide sponsorship support, athletic training ... association coaches, volunteers, athletes and families. ... Sports Association and to bring Houston Methodist quality ...
(Date:6/23/2016)... --  EpiBiome , a precision microbiome engineering company, today ... from Silicon Valley Bank (SVB). The financing will allow ... drug development efforts, as well as purchase additional lab ... been an incredible strategic partner to us – one ... provide," said Dr. Aeron Tynes Hammack , EpiBiome,s ...
(Date:6/23/2016)... Ky. , June 23, 2016 ... two Phase 1 clinical trials of its complement ... placebo-controlled, single and multiple ascending dose studies designed ... pharmacodynamics (PD) of subcutaneous injection in healthy adult ... subcutaneously (SC) either as a single dose (ranging ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, ... Pennsylvania Convention Center and will showcase its product’s latest features from June 26 ... presenting a scientific poster on Disrupting Clinical Trials in The Cloud during the ...
Breaking Biology Technology:
(Date:6/3/2016)... 2016 Das DOTM ... Nepal hat ein 44 Millionen ... Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, an ... und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte internationale ... teilgenommen, aber Decatur wurde als konformste und ...
(Date:5/24/2016)... 24, 2016 Ampronix facilitates superior patient care by providing unparalleled technology to ... display is the latest premium product recently added to the range of products distributed ... ... ... Imaging- LCD Medical Display- Ampronix News ...
(Date:5/3/2016)... Lithuania , May 3, 2016  Neurotechnology, ... released the MegaMatcher Automated Biometric Identification System ... of large-scale multi-biometric projects. MegaMatcher ABIS can process ... accuracy using any combination of fingerprint, face or ... MegaMatcher SDK and MegaMatcher Accelerator ...
Breaking Biology News(10 mins):